Abstract
The effectiveness of therapies for chronic hepatitis B will depend on their ability to inhibit all HBV replicative intermediates including viral SC DNA as well as stimulating the host's immune system to clear virus and produce sustained immunity. Future therapies will require the use of combined treatments in 'cocktail-type arrangements' as outlined in this paper, linked with careful staging of the hepatitis B carrier state.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
